Authors


Raghu Kalluri, MD, PhD

Latest:

Using Exosomes to Help Cancer Diagnosis

Dr. Raghu Kalluri speaks with Cancer Network about the role of exosomes in cancer progression ahead of his presentation at ESMO 2018.


Traci DeVito

Latest:

FDA Approves Two New Indications and Dosage Form for Pembrolizumab

In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.


William Pirl, MD

Latest:

Managing Anxiety and Depression in Cancer Patients

Dr. William Pirl speaks with Cancer Network about cancer patients' moods influencing their well-being and survival.


Jennifer Leavitt, MS

Latest:

2019 World Conference Of Lung Cancer Round-Up

Five notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).


Katarzyna J. Jerzak, MD, MSc, FRCPC

Latest:

Bone-Targeted Therapy in Early Breast Cancer

In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.


Jacques Raphael, MD, MSc, FRCPC

Latest:

Bone-Targeted Therapy in Early Breast Cancer

In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.


Danielle N. Desautels, MD, MSc, FRCPC

Latest:

Bone-Targeted Therapy in Early Breast Cancer

In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.


Ivan Tyono, BScPhm, RPh

Latest:

Bone-Targeted Therapy in Early Breast Cancer

In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.


Suzanna Maria Zick, ND, MPH

Latest:

Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.


Detrick Snyder, MPH

Latest:

Pros and Cons of Dietary Strategies Popular Among Cancer Patients

This article discusses some of the popular diets that cancer patients pursue, and the positive and negative aspects associated with these diets.


Ronan Kelly, MD, MBA

Latest:

Considerations in the Care of Non–Small-Cell Lung Cancer: The Value Imperative

This article discusses ways in which the oncologist can incorporate value into the management of patients with lung cancer and comply with the underlying principles of the Choose Wisely Campaign, as well as recent ASCO and ESMO initiatives, to bend the cost curve downwards while maintaining efficacy.


Stefanie Houseknecht, PharmD, BCOP

Latest:

Considerations in the Care of Non–Small-Cell Lung Cancer: The Value Imperative

This article discusses ways in which the oncologist can incorporate value into the management of patients with lung cancer and comply with the underlying principles of the Choose Wisely Campaign, as well as recent ASCO and ESMO initiatives, to bend the cost curve downwards while maintaining efficacy.


Karisa C. Schreck, MD, PhD

Latest:

Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System

In this article, we review the role of temozolomide in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers.


Denise L. Faustman, MD, PhD

Latest:

TNFR2's Role in Influencing Tumor Tissue

Dr. Denise Faustman spoke with Cancer Network about TNFR2 and its emerging role in understanding regulatory T-cell behavior.


William Newman, PhD, FRCP

Latest:

Epigenetics, BRCA, and Inherited Cancers: Dr. Newman Connects the Dots

Dr. William Newman spoke with Cancer Network about the roles of epigenetic silencing in heritable cancer syndromes.


Minetta C. Liu, MD

Latest:

ctDNA Positivity Appears to Predict Risk of Recurrence, Benefit from Adjuvant Chemotherapy in Resectable CRC

An expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.


Filip Janku, MD, PhD

Latest:

Bacterial Therapy May Be Promising in Cancer Patients

Dr. Filip Janku speaks with Cancer Network about a phase I clinical trial investigating the use of bacterial clostridium novyi-NT in solid tumors.


Stephanie Jackson, MSN, RN

Latest:

Managing CAR T-Cell Therapy in Patients With Hematologic Malignancies

Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.


Christina Bennett, MS

Latest:

Panitumumab Helps Colorectal Cancer Patients Get to Surgery

The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.


Xinyu Nan, MD

Latest:

Immunotherapeutic Approaches to the Management of Head and Neck Cancer

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.


Kathryn A. Gold, MD

Latest:

Immunotherapeutic Approaches to the Management of Head and Neck Cancer

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.


Ezra Cohen, MD

Latest:

Immunotherapeutic Approaches to the Management of Head and Neck Cancer

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.


Mona S. Patel, DO

Latest:

Strategies for the Optimal Management of Dyspnea in Cancer Patients With Advanced Illness

In this article, Dr. Mona Patel discusses how to best manage dyspnea in cancer patients, with both pharmacologic and nonpharmacologic approaches.


Meagan A. Jacoby, MD, PhD

Latest:

Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome

In this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.


Matthew Walter, MD

Latest:

Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome

In this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.


Karen E. Knudsen, PhD

Latest:

COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?

In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.


Ni-Chun Chung, MSc

Latest:

Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS Malignancies

This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.


Adam K. Walker, PhD

Latest:

Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS Malignancies

This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.


Haryana M. Dhillon, PhD

Latest:

Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS Malignancies

This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.


Janette L. Vardy, MD, PhD

Latest:

Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS Malignancies

This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.